NanoLogix Study Confirms Early Success Of Hydrogen Bioreactor

NanoLogix, Inc., (Pink Sheets: IFEC - News), a Nanobiotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials, announces that preliminary data and results of a study which confirms laboratory proof-of-concept measurements have shown it possible to generate hydrogen in high yields via the use and adaptation of its intellectual property. In this study, the bioreactor produced biogas consisting of 50% hydrogen by volume, without any trace of methane.

Recently, NanoLogix, Inc. (formerly Infectech, Inc.) signed a feasibility study with the Department of Environmental Science and Engineering of Gannon University in Erie, PA to develop a bioreactor which utilizes NanoLogix's patented bacterial culturing methods in order to produce hydrogen inexpensively. Hydrogen reacts with oxygen to yield significant amounts of energy, and has the added benefit of not producing carbon dioxide as a by-product (the reaction between hydrogen and oxygen simply generates water vapor). NanoLogix believes they have discovered the most likely method for low cost production of massive quantities of hydrogen as an alternate energy source. NanoLogix has ascertained through its patent counsel that additional patents will be pending beyond those already filed.